- Trials with a EudraCT protocol (38,630)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
38,630 result(s) found for: decitabine OR 2'-.
Displaying page 17 of 1,932.
EudraCT Number: 2015-004768-12 | Sponsor Protocol Number: NN5401-4266 | Start Date*: 2016-08-10 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without o... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003731-22 | Sponsor Protocol Number: MK-0431A-296 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000186-76 | Sponsor Protocol Number: MK-4117-200 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects with Perennial Allergic Rhinitis. | |||||||||||||
Medical condition: Perennial allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003374-10 | Sponsor Protocol Number: TOC106489 | Start Date*: 2007-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated... | ||
Medical condition: Uncomplicated skin and skin structure infections | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000472-37 | Sponsor Protocol Number: NN1436-4479 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week double blinded, multiregional, trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001155-40 | Sponsor Protocol Number: 16032020 | Start Date*: 2020-08-20 | ||||||||||||||||
Sponsor Name:Steno Diabetes Center Copenhagen | ||||||||||||||||||
Full Title: Kidney Fat in Type 2 Diabetes & Diabetic Kidney Disease and the Effects of Ezetimibe: A Cross-Sectional Study and Randomized, Placebo-Controlled Trial | ||||||||||||||||||
Medical condition: Type 2 diabetes, diabetic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003339-53 | Sponsor Protocol Number: I8H-MC-BDCL | Start Date*: 2020-09-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003037-11 | Sponsor Protocol Number: 21839 | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants wi... | |||||||||||||
Medical condition: Chronic kidney disease in type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022718-17 | Sponsor Protocol Number: 1245.31 | Start Date*: 2011-03-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (... | |||||||||||||
Medical condition: Type 2 Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) SK (Completed) SI (Completed) BE (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004392-12 | Sponsor Protocol Number: NN9535-3625 | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) SK (Completed) DE (Completed) GB (Completed) NL (Completed) RO (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001108-40 | Sponsor Protocol Number: MK-5475-007 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005385-39 | Sponsor Protocol Number: EFC10007 | Start Date*: 2007-06-14 | |||||||||||
Sponsor Name:sanofi-aventis recherche et developpement | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control with Rimonabant in Comparison with Glimepiride over 1 Year in Overweight/Obese Type 2 Diabeti... | |||||||||||||
Medical condition: Overweight/Obese Type 2 Diabetic Patients Not Adequately Controlled with Metformin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Prohibited by CA) FI (Completed) ES (Completed) DK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004827-19 | Sponsor Protocol Number: NN9535-3626 | Start Date*: 2013-10-01 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BG (Completed) PT (Completed) ES (Completed) HU (Completed) CZ (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002801-20 | Sponsor Protocol Number: NN1250-4252 | Start Date*: 2017-02-10 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without ora... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) DK (Completed) EE (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000540-24 | Sponsor Protocol Number: CLAF237A2310 | Start Date*: 2004-12-15 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type... | ||
Medical condition: Type II Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) IE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003851-45 | Sponsor Protocol Number: CAEB1102-101A | Start Date*: 2018-03-14 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102 | |||||||||||||
Medical condition: Arginase 1 deficiency Hyperargininemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001061-24 | Sponsor Protocol Number: KBP042/CD/003 | Start Date*: 2017-08-11 | |||||||||||
Sponsor Name:KeyBioscience AG | |||||||||||||
Full Title: A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-042 in Patients with Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003621-18 | Sponsor Protocol Number: NN9068-4185 | Start Date*: 2015-06-03 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: DUAL™VII - Insulin degludec/liraglutide (IDegLira) vs. basal-bolus therapy: A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in s... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) GR (Completed) ES (Completed) CZ (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003842-34 | Sponsor Protocol Number: MK-5592-127 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formul... | |||||||||||||
Medical condition: Invasive Fungal Infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) Outside EU/EEA BE (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021069-63 | Sponsor Protocol Number: BCB109(H8O-MC-GWDQ) | Start Date*: 2011-06-23 | |||||||||||
Sponsor Name:Amylin Pharmaceuticals, LLC | |||||||||||||
Full Title: A randomized, placebo, controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide Once Weekly in patients with type 2 diabetes mellitus | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) LV (Completed) AT (Completed) GB (Completed) CZ (Completed) SK (Completed) HU (Completed) BG (Completed) IT (Completed) BE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
